Compare CASS & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CASS | FBRX |
|---|---|---|
| Founded | 1906 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 596.8M | 487.2M |
| IPO Year | 1996 | 2017 |
| Metric | CASS | FBRX |
|---|---|---|
| Price | $46.41 | $21.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $45.00 | ★ $67.00 |
| AVG Volume (30 Days) | 54.5K | ★ 191.2K |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.75% | N/A |
| EPS Growth | ★ 87.77 | 61.30 |
| EPS | ★ 0.67 | N/A |
| Revenue | ★ $190,750,000.00 | $36,000.00 |
| Revenue This Year | $0.81 | N/A |
| Revenue Next Year | $4.39 | N/A |
| P/E Ratio | $69.36 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $36.07 | $7.78 |
| 52 Week High | $52.45 | $35.80 |
| Indicator | CASS | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.59 | 39.84 |
| Support Level | $45.20 | $18.18 |
| Resistance Level | $47.93 | $22.61 |
| Average True Range (ATR) | 1.11 | 1.95 |
| MACD | -0.04 | -0.16 |
| Stochastic Oscillator | 53.26 | 36.36 |
Cass Information Systems Inc is a provider of payment and information processing services to large manufacturing, distribution, and retail enterprises across the United States. The company provides transportation invoice rating, payment processing, auditing, accounting, and transportation information. It is also a processor and payer of energy invoices, including electricity, gas, waste, and other facility-related expenses. Additionally, the firm has a banking subsidiary, offering banking services mainly to privately held businesses in the St. Louis metropolitan area and restaurant franchises and faith-based ministries within the United States. The company operates in two reportable segments: Information Services, which generates the maximum revenue, and Banking Services.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.